These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 1634914)
1. LOPP alternating with EVAP is superior to LOPP alone in the initial treatment of advanced Hodgkin's disease: results of a British National Lymphoma Investigation trial. Hancock BW; Vaughan Hudson G; Vaughan Hudson B; Bennett MH; MacLennan KA; Haybittle JL; Anderson L; Linch DC J Clin Oncol; 1992 Aug; 10(8):1252-8. PubMed ID: 1634914 [TBL] [Abstract][Full Text] [Related]
2. Hybrid LOPP/EVA is not better than LOPP alternating with EVAP: a prematurely terminated British National Lymphoma Investigation randomized trial. Hancock BW; Vaughan Hudson G; Vaughan Hudson B; Linch DC; Anderson L; MacLennan KA Ann Oncol; 1994; 5 Suppl 2():117-20. PubMed ID: 8204511 [TBL] [Abstract][Full Text] [Related]
3. ChlVPP alternating with PABlOE is superior to PABlOE alone in the initial treatment of advanced Hodgkin's disease: results of a British National Lymphoma Investigation/Central Lymphoma Group randomized controlled trial. Hancock BW; Gregory WM; Cullen MH; Hudson GV; Burton A; Selby P; Maclennan KA; Jack A; Bessell EM; Smith P; Linch DC; ; Br J Cancer; 2001 May; 84(10):1293-300. PubMed ID: 11355937 [TBL] [Abstract][Full Text] [Related]
4. Randomized study for the treatment of advanced Hodgkin's disease: MOPP vs. LOPP. Avilés A; Díaz-Maqueo JC; García EL; Torras V; López-Vancell D Arch Invest Med (Mex); 1991; 22(1):45-50. PubMed ID: 1819976 [TBL] [Abstract][Full Text] [Related]
5. British National Lymphoma Investigation randomised study of MOPP (mustine, Oncovin, procarbazine, prednisolone) against LOPP (Leukeran substituted for mustine) in advanced Hodgkin's disease--long term results. Hancock BW; Vaughan Hudson G; Vaughan Hudson B; Haybittle JL; Bennett MH; MacLennan KA; Jelliffe AM Br J Cancer; 1991 Apr; 63(4):579-82. PubMed ID: 2021542 [TBL] [Abstract][Full Text] [Related]
6. Trials in advanced Hodgkin's disease: more than 30 years experience of the British National Lymphoma Investigation. Zekri JM; Mouncey P; Hancock BW Clin Lymphoma; 2004 Dec; 5(3):174-83. PubMed ID: 15636693 [TBL] [Abstract][Full Text] [Related]
7. ChlVPP/PABlOE and radiotherapy in advanced Hodgkin's disease. The Central Lymphoma Group. Cullen MH; Stuart NS; Woodroffe C; Murphy A; Fletcher J; Blackledge GR; Child JA; Grieve RJ; Jones EL J Clin Oncol; 1994 Apr; 12(4):779-87. PubMed ID: 7512132 [TBL] [Abstract][Full Text] [Related]
8. Results of a randomized trial comparing MVPP chemotherapy with a hybrid regimen, ChlVPP/EVA, in the initial treatment of Hodgkin's disease. Radford JA; Crowther D; Rohatiner AZ; Ryder WD; Gupta RK; Oza A; Deakin DP; Arnott S; Wilkinson PM; James RD J Clin Oncol; 1995 Sep; 13(9):2379-85. PubMed ID: 7666097 [TBL] [Abstract][Full Text] [Related]
9. Randomized trial of CVPP for three versus six cycles in favorable-prognosis and CVPP versus AOPE plus radiotherapy in intermediate-prognosis untreated Hodgkin's disease. Pavlovsky S; Schvartzman E; Lastiri F; Magnasco H; Corrado C; Raslawski E; Cancela ME; Ardaiz MC; Cerutti I; Rosso A; Bruno S; Aranguren PN; Salvarezza A; Donato H; Dibar E; Zirone S J Clin Oncol; 1997 Jul; 15(7):2652-8. PubMed ID: 9215837 [TBL] [Abstract][Full Text] [Related]
10. Randomised study of MOPP (mustine, Oncovin, procarbazine, prednisone) against LOPP (Leukeran substituted for mustine) in advanced Hodgkin's disease. British National Lymphoma Investigation. Hancock BW Radiother Oncol; 1986 Nov; 7(3):215-21. PubMed ID: 3544084 [TBL] [Abstract][Full Text] [Related]
11. Etoposide, vinblastine, adriamycin and prednisolone (EVAP) combination chemotherapy as first-line treatment for Hodgkin's disease. Raina V; Sharma A; Mohanti BK; Kumar R; Dawar R; Rath GK Natl Med J India; 2003; 16(4):199-203. PubMed ID: 14606767 [TBL] [Abstract][Full Text] [Related]
12. Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5. Sieber M; Tesch H; Pfistner B; Rueffer U; Lathan B; Brosteanu O; Paulus U; Koch T; Pfreundschuh M; Loeffler M; Engert A; Josting A; Wolf J; Hasenclever D; Franklin J; Duehmke E; Georgii A; Schalk KP; Kirchner H; Doelken G; Munker R; Koch P; Herrmann R; Greil R; Anselmo AP; Diehl V J Clin Oncol; 2002 Jan; 20(2):476-84. PubMed ID: 11786577 [TBL] [Abstract][Full Text] [Related]
13. A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial. Somers R; Carde P; Henry-Amar M; Tarayre M; Thomas J; Hagenbeek A; Monconduit M; de Pauw BE; Breed WP; Verdonck L J Clin Oncol; 1994 Feb; 12(2):279-87. PubMed ID: 7509381 [TBL] [Abstract][Full Text] [Related]
14. Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group. Connors JM; Klimo P; Adams G; Burns BF; Cooper I; Meyer RM; O'Reilly SE; Pater J; Quirt I; Sadura A; Shustik C; Skillings J; Sutcliffe S; Verma S; Yoshida S; Zee B J Clin Oncol; 1997 Apr; 15(4):1638-45. PubMed ID: 9193364 [TBL] [Abstract][Full Text] [Related]
15. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group. Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V; J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249 [TBL] [Abstract][Full Text] [Related]
16. ChlVPP/ABVVP, a first line 'hybrid' combination chemotherapy for advanced Hodgkin's lymphoma: a retrospective analysis. Martinelli G; Cocorocchio E; Peccatori F; Zucca E; Saletti PC; Calabrese L; Pastano R; Pruneri G; Mazzetta C; Ghielmini M; Cavalli F Br J Haematol; 2004 Jun; 125(5):584-9. PubMed ID: 15147373 [TBL] [Abstract][Full Text] [Related]
17. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. Diehl V; Franklin J; Hasenclever D; Tesch H; Pfreundschuh M; Lathan B; Paulus U; Sieber M; Rueffer JU; Sextro M; Engert A; Wolf J; Hermann R; Holmer L; Stappert-Jahn U; Winnerlein-Trump E; Wulf G; Krause S; Glunz A; von Kalle K; Bischoff H; Haedicke C; Duehmke E; Georgii A; Loeffler M J Clin Oncol; 1998 Dec; 16(12):3810-21. PubMed ID: 9850026 [TBL] [Abstract][Full Text] [Related]
18. Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin's lymphoma. Aleman BM; Raemaekers JM; Tomiŝiĉ R; Baaijens MH; Bortolus R; Lybeert ML; van der Maazen RW; Girinsky T; Demeestere G; Lugtenburg P; Lievens Y; de Jong D; Pinna A; Henry-Amar M; Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):19-30. PubMed ID: 17097834 [TBL] [Abstract][Full Text] [Related]
19. Low-dose radiation therapy and reduced chemotherapy in childhood Hodgkin's disease: the experience of the French Society of Pediatric Oncology. Oberlin O; Leverger G; Pacquement H; Raquin MA; Chompret A; Habrand JL; Terrier-Lacombe MJ; Bey P; Bertrand Y; Rubie H J Clin Oncol; 1992 Oct; 10(10):1602-8. PubMed ID: 1383434 [TBL] [Abstract][Full Text] [Related]
20. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. Gobbi PG; Levis A; Chisesi T; Broglia C; Vitolo U; Stelitano C; Pavone V; Cavanna L; Santini G; Merli F; Liberati M; Baldini L; Deliliers GL; Angelucci E; Bordonaro R; Federico M; J Clin Oncol; 2005 Dec; 23(36):9198-207. PubMed ID: 16172458 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]